Associate Professor in Paediatrics and Vaccinology
- BRC Consultant in Paediatrics and Vaccinology
Dr Matthew Snape, MBBS FRCPCH MD, is a Consultant in General Paediatrics and Vaccinology at the NIHR Oxford Biomedical Research Council and the Children’s Hospital Oxford, Oxford University Hospitals NHS Trust. He is also an Honorary Senior Clinical Lecturer at the Department of Paediatrics, University of Oxford, a Jenner Investigator and a fellow of St Cross College, Oxford.
Dr Snape graduated from the University of Melbourne in 1993 and completed his basic paediatric training at the Royal Children’s Hospital, Melbourne before continuing his training at St Mary’s Hospital, London. While working in the Paediatric Intensive Care Unit at St Mary’s hospital he became interested in the prevention of invasive meningococcal disease by immunisation, and on completion of his clinical training took up a post as a research fellow (later Clinical Lecturer) at the Oxford Vaccine Group, University of Oxford. While here he completed his post- graduate Doctor of Medicine (MD) degree, awarded by the University of Melbourne in 2009. He has been employed as a Consultant in General Paediatrics and Vaccinology by the Oxford University Hospitals NHS Trust since 2009. His principal areas of research relate to vaccines against meningococcal, pneumococcal, influenza and ebola disease, and prevention of disease through maternal immunisation.
Dr Snape was acknowledged as an NIHR Clinical Research Network ‘Leading Commercial Principal Investigator’ in 2015 by Dame Sally Davis, Chief Medical Office, and has published over 70 manuscripts relating to immunisation. He is also a member of the Meningitis Research Foundation's Medical Advisory Group.
Dr Snape is an Academic Training Programme Director for Oxford University Clinical Academic Graduate School (OUCAGS), with a particular focus on paediatric academic training.
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R. et al, (2018), Vaccine
Antenatal vaccination against Group B streptococcus: attitudes of pregnant women and healthcare professionals in the UK towards participation in clinical trials and routine implementation.
McQuaid F. et al, (2018), Acta Obstet Gynecol Scand, 97, 330 - 340
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.
Goldblatt D. et al, (2018), Lancet Infect Dis, 18, 171 - 179
Differences in Immunization Site Pain in Toddlers Vaccinated with Either the 10- or the 13-Valent Pneumococcal Conjugate Vaccine.
Trück J. et al, (2018), The Pediatric infectious disease journal
Respiratory syncytial virus seasonality and its implications on prevention strategies.
Janet S. et al, (2018), Hum Vaccin Immunother, 14, 234 - 244